October 25, 2019MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
October 22, 2019MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer
September 25, 2019T2 Biosystems’ T2Resistance™ Panel is First Diagnostic to Graduate from CARB-X Portfolio
September 10, 2019T2 Biosystems Awarded Breakthrough Technology Contract with Premier Inc.
August 16, 2019T2 Biosystems Expands Access to its Innovative Rapid Diagnostic Technologies to Australia, Fiji and New Zealand
August 6, 2019T2Bacteria Panel is the First and Only In-Vitro Diagnostic Test to Receive Approval for a New Technology Add-on Payment by CMS
August 1, 2019I-Mab Biopharma And TRACON Pharmaceuticals Announce Dosing Of The First Patient In The U.S. Phase 1 Clinical Trial Of The CD73 Antibody TJD5 In Patients With Advanced Solid Tumors
July 26, 2019T2 Biosystems Expands Global Access to its Innovative Rapid Diagnostic Technologies
July 17, 2019MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
July 10, 2019MacroGenics and I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China
July 2, 2019TRACON Pharmaceuticals Provides Update On Phase 1/2 Trial Of TRC253 In Patients With Metastatic Castrate Resistant Prostate Cancer